Anti-VEGF
Skill needed for challenging staging, treatment of ROP
Retinopathy of prematurity occurs primarily in low birth weight premature infants who are admitted to a neonatal intensive care unit and require oxygen supplementation.
The Retina Radar With Dr. Arshad Khanani on Gene Therapy, TKIs, Emerging Treatments, and FDA Trial Guidance
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
In Case You Missed...Evolving Management Protocols for Retinal Diseases
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Community Practice Connections: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes
This activity is supported by Regeneron Pharmaceuticals, Inc.
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
In Case You Missed…Translating the Latest Clinical Trial Insights Into Retinal Disease Management
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
The Retina Radar With Dr. Arshad Khanani on CTS, nAMD, DME, and Sustained Delivery
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Summer breezes: Thoughts while I sits and thinks
It’s hot outside. Like the heat of my youth hot. My sleeping dogs, companions for all my previous “sits and thinks” summer columns, will only lie indoors with the air conditioning on.
Do you expect to use more biosimilars in the future?
Undoubtedly, cost can be a barrier to optimal anti-VEGF treatment in the United States and around the world.
Biosimilars have yet to make an impact in ophthalmology
It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S.